<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wu Q</submitter><funding>Science and Technology Planning Project of Guangdong Province</funding><funding>China Postdoctoral Science Foundation</funding><funding>National Natural Science Foundation of China</funding><funding>Provincial Major Scientific Research Projects at Universities of Guangdong Province</funding><pagination>1081-1096</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10976599</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>4(3)</volume><pubmed_abstract>Lysosome-targeted photodynamic therapy, which enhances reactive oxygen species (ROS)-responsive tumor cell death, has emerged as a promising strategy for cancer treatment. Herein, a uridine (dU)-modified Ru(II) complex (RdU) was synthesized by click chemistry. It was found that RdU exhibits impressive photo-induced inhibition against the growth of triple-negative breast cancer (TNBC) cells in normoxic and hypoxic microenvironments through ROS production. It was further revealed that RdU induces ferroptosis of MDA-MB-231 cells under light irradiation (650 nm, 300 mW/cm&lt;sup>2&lt;/sup>). Additional experiments showed that RdU binds to lysosomal integral membrane protein 2 (LIMP-2), which was confirmed by the fact that RdU selectively localizes in the lysosomes of MDA-MB-231 cells and significant</pubmed_abstract><journal>JACS Au</journal><pubmed_title>Uridine-Modified Ruthenium(II) Complex as Lysosomal LIMP-2 Targeting Photodynamic Therapy Photosensitizer for the Treatment of Triple-Negative Breast Cancer.</pubmed_title><pmcid>PMC10976599</pmcid><funding_grant_id>2017M610576</funding_grant_id><funding_grant_id>2014KZDXM053</funding_grant_id><funding_grant_id>81572926</funding_grant_id><funding_grant_id>2014A020212312</funding_grant_id><funding_grant_id>81703349</funding_grant_id><pubmed_authors>Li G</pubmed_authors><pubmed_authors>Yuan C</pubmed_authors><pubmed_authors>Mei W</pubmed_authors><pubmed_authors>Wu Q</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Zhu C</pubmed_authors><pubmed_authors>Lv Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>Uridine-Modified Ruthenium(II) Complex as Lysosomal LIMP-2 Targeting Photodynamic Therapy Photosensitizer for the Treatment of Triple-Negative Breast Cancer.</name><description>Lysosome-targeted photodynamic therapy, which enhances reactive oxygen species (ROS)-responsive tumor cell death, has emerged as a promising strategy for cancer treatment. Herein, a uridine (dU)-modified Ru(II) complex (RdU) was synthesized by click chemistry. It was found that RdU exhibits impressive photo-induced inhibition against the growth of triple-negative breast cancer (TNBC) cells in normoxic and hypoxic microenvironments through ROS production. It was further revealed that RdU induces ferroptosis of MDA-MB-231 cells under light irradiation (650 nm, 300 mW/cm&lt;sup>2&lt;/sup>). Additional experiments showed that RdU binds to lysosomal integral membrane protein 2 (LIMP-2), which was confirmed by the fact that RdU selectively localizes in the lysosomes of MDA-MB-231 cells and significant</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-19T10:14:48.946Z</modification><creation>2025-04-19T10:14:48.946Z</creation></dates><accession>S-EPMC10976599</accession><cross_references><pubmed>38559730</pubmed><doi>10.1021/jacsau.3c00808</doi></cross_references></HashMap>